FDA Clearance Tracker · P140029-S054
Restylane® Contour
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 20, 2026
Approved
Time to decision
239 days
Received Jul 24, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for expanding the indications of Restylane Contour for correction of temple hollowing in patients over the age of 21.
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® Lyft with LidocainePMA supplement
P040024-S142 · Decided Nov 4, 2025 · 278 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.